Validation and analysis of key factors of Banxia Xiexin decoction against gastric cancer

Table 3 Comparison of relative expression of phosphatidylinositol 3-kinase/AKT signaling pathway related proteins in each group

Group	PIK3CA	HSP90AA1	PIK3R1	AKT1	TP53
GES-1	0.27 ± 0.007	0.29 ± 0.05	0.22 ± 0.002	0.21 ± 0.005	0.24 ± 0.03
AGS	0.82 ± 0.036b	0.96 ± 0.029b	0.87 ± 0.014b	0.9 ± 0.085a	0.85 ± 0.032b
Capecitabine	0.45 ± 0.05c	0.57 ± 0.018d	0.54 ± 0.01d	0.48 ± 0.03c	0.55 ± 0.033c
BXD	0.59 ± 0.05	0.72 ± 0.04c	0.73 ± 0.021c	0.63 ± 0.007	0.63 ± 0.063
LY294002	0.57 ± 0.015c	0.64 ± 0.039c	0.66 ± 0.005d	0.57 ± 0.013	0.61 ± 0.006c
BXD + LY	0.37 ± 0.023d	0.42 ± 0.006d	0.47 ± 0.009d	0.34 ± 0.022c	0.37 ± 0.028d

^aP < 0.05 vs GES-1.

^bP < 0.01 vs GES-1.

^cP < 0.05 vs AGS.

^dP < 0.01 vs AGS.

PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; HSP90AA1: Heat shock protein 90 alpha family class A member 1; PIK3R1: Phosphoinositide-3-kinase regulatory subunit 1; AKT1: AKT serine/threonine kinase 1; TP53: Tumor protein p53; BXD: Banxia Xiexin decoction; LY: LY294002.